1Department of Cardiovascular Medicine, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan
2Department of Cancer Pathology, Faculty of Medicine, Hokkaido University, Sapporo, Japan
Address for correspondence:Takao Konishi, MD, PhD, Department of Cardiovascular Medicine, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, West 7, North 15, Kita-ku, Sapporo, 060-8638, Japan, tel: +81-11-706-6973, fax: +81-11-706-7874, e-mail: takaokonishi0915@gmail.com
Received: 2.06.2021 Accepted: 11.10.2021
This article is available in open access under Creative Common Attribution-Non-Commercial-No Derivatives 4.0 International (CC BY-NC-ND 4.0) license, allowing to download articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially.
A 35-year-old man was admitted to our hospital due to acute coronary syndrome (ACS). One year before, he was diagnosed with familial hypercholesterolemia (FH), and a stent was implanted in his left anterior descending artery and the left circumflex artery due to ACS. Despite receiving combination therapy of rosuvastatin 20 mg/day and ezetimibe 10 mg/day, his low-density lipoprotein cholesterol (LDL-C) concentration was 100 mg/dL at the second ACS. Emergency coronary angiography (CAG) revealed total occlusion of the middle right coronary artery (Fig. 1A). An intravascular ultrasound study suggested plaque rupture (Fig. 1B, arrow). Aspiration thrombectomy and stent implantation facilitated a grade 3 Thrombolysis in Myocardial Infarction flow in the final CAG. Histopathological examination of the aspirated thrombi showed a luminal thrombus (arrowhead) communicating with the underlying necrotic core with numerous cholesterol clefts (Fig. 1C-a). Inflammatory cells, including foamy and hemosiderin-laden macrophages, were also observed (Fig. 1C-b). These findings suggest that intensive lipid-lowering therapy using statin and ezetimibe was insufficient to stabilize the vulnerable plaque in a patient with FH when the targeted LDL-C level was not achieved. No further ACS has been documented after administration of proprotein convertase subtilisin/kexin type 9 inhibitor for secondary prevention over a 14-month follow-up.
Figure 1. A. The initial coronary angiogram; B. The intravascular ultrasound study; C. Histopathology of aspirated thrombi showing (a) cholesterol clefts and (b) inflammatory cells including foamy and hemosiderin-laden macrophages.
Conflict of interest: None declared
This site uses cookies
We use cookies on our website. We use them to ensure the proper functioning of the site and, if you give us your consent, for purposes we set, such as analytics or marketing. We would like to ask your permission to store them on your device. We will not run optional cookies until you have enabled them yourself. If you would like to learn more about how cookies work and how we process personal data related to them, please visit our Privacy Policy page
About cookies
Necessary cookies
Allways active
These cookies are necessary for the proper display and operation of the website. Blocking them may cause the website to malfunction.
Analytical cookies
As part of our website, we use analytical tools, such as Google Analytics, that allow us to verify website traffic. These tools may require the use of cookies.
Community cookies
These are cookies associated with the social networks we use. Accepting them will allow us to associate your visit to the site with our social media profiles.
Marketing cookies
These are cookies responsible for carrying out advertising and marketing activities - consenting to their use will allow us to target you with advertisements based on your previous activities within our website.